THERAPY DOSSIER · th-d977438bc4fe

Protocatechuic acid

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06121362 ↗NAwithdrawn

Effect of protocatechuic acid on biochemical markers of immunity status in healthy adults

Immunity

Enrolment: 0 · Results not recorded

NCT06591741 ↗NAnot yet recruiting

Dietary protocatechuic acid in participants with knee prosthetic joint infection

Prosthetic Joint Infection

Enrolment: 100 · Results not recorded

NCT06591728 ↗NAnot yet recruiting

Dietary protocatechuic acid in prosthetic joint infection before revision surgery

Prosthesis-Related Infections

Enrolment: 10 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23117377 ↗2012Reported benefit

Suppression of the p66shc adapter protein by protocatechuic acid prevents the development of lung injury induced by intestinal ischemia reperfusion in mice.

MouseIschaemia-reperfusionIntestinal / mesentericICRn = 50 mice, five groups of 10IntraperitonealLow dose and high dose groups; numerical doses not stated i…Pretreatment before ischaemia

Model: Superior mesenteric artery occlusion 45 min then reperfusion 90 min, with remote lung injury

Protocatechuic acid pretreatment reduced lung histological injury, lowered TNF-alpha, interleukin 6 and caspase-3, and raised glutathione, MnSOD and Bcl-xL.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…